The epidemic level of MERS-CoV infection was examined in Saudi Arabia by the Susceptible-Infectious-Recovered model using a Bayesian approach for estimation of time dependent reproduction number across a two-year interval.
Since 2012, a total of 2,090 laboratory-confirmed Middle East respiratory syndrome (MERS) cases worldwide have been reported.
MERS coronavirus appears to have emerged in humans in Saudi Arabia in 2012, but has been traced back in camels to at least 1983.
Representatives from the Ministries of Health and Ministries of Agriculture of affected and at-risk countries have agreed on next steps to accelerate the response to the threat posed by Middle East respiratory syndrome coronavirus (MERS-CoV).
Researchers describe the occurrence of an outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) among healthcare workers and characterize at-risk exposures to improve future infection control interventions.
Michael Osterholm discusses the threat of Middle East respiratory syndrome (MERS) on a larger scale and what can be done to prevent it.
This increases the cases to 1,622, including 695 deaths since 2012.
Inovio Pharmaceuticals and GeneOne Life Sciences have started human testing of their Middle East respiratory syndrome (MERS) vaccine in South Korea.
The infection was reported in a 54-year-old male from Musannah.
As Middle East respiratory syndrome coronavirus (MERS-CoV) risk-standardized mortality rates are currently unavailable, the author sought to develop a method to estimate the risk-standardized mortality rates using MERS-CoV three and 30 day mortality measures.